Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Nona Biosciences

This biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer.

HBM gets health boost from drug licensing deals

The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
December 22, 2023
2142.HK

HBM rises from the ashes as a research partner for drug giants

The cash-strapped company disposed of a factory and an advanced drug pipeline to stay in business, and is now re-positioning itself as a supplier of biomedical services Key Takeaways: HBM…
April 6, 2023
2142.HK

Recent Articles

This biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer.
December 22, 2023

HBM gets health boost from drug licensing deals

2142.HK
April 6, 2023

HBM rises from the ashes as a research partner for drug giants

2142.HK

RELATED ARTICLES

  1. TYK Medicines
    March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  2. February 21, 2025
    As Covid drug cash dwindles, Vigonvita targets new remedies
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.